We've put some small files called cookies on your device to make our site work.
We'd also like to use analytics cookies. These send information about how our site is used to a service called Google Analytics. We use this information to improve our site.
Let us know if this is OK. We'll use a cookie to save your choice. You can read more about our cookies before you choose.
This document is a clinical commissioning policy statement on Pembrolizumab for drug-resistant gestational trophoblastic neoplasia and is an interim commissioning position pending the formation of a Clinical Policy.
